SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?


To: SOROS who wrote (882)6/23/1998 9:53:00 PM
From: Michael M. Cubrilo  Respond to of 1185
 
Soros.... lets hope the flying rats are right. I am waiting for the uptick, there will be plenty of opportunity to invest once the chart turns. She is still a blue ski run in the down direction, almost back to my original purchase price. However, I do feel that we are approaching the base. Definately time to get in line for the ski lift, I just have not reached the empty chair yet... I'll wait until the lift speeds up and I see the momentum of the crowd picking up.

We are due for some news though... it has been pretty dry lately. Profits are on the sidelines, waiting for the reentry. I would like to say "soon"?

mike



To: SOROS who wrote (882)6/24/1998 1:33:00 AM
From: Wisee  Read Replies (1) | Respond to of 1185
 
To All,

A friend of mine brought to my attention a stock called Medco Research
(MRE on AMAX). Medco is working on drug that helps patients after a
heart attack. Their drug is presently in Phase III trials.
Medco's market cap is $243 million US or $350 million CAN.

If Hoffman LaRoche exercise their option on Nortran's antiarrhythmic compounds, I would suspect that they would fast track the tests to Phase III within 36 months. Nortran would trade at $10+, similar to what Medco's market cap. is today.

We also have to remember that Nortran has several other potential
"blockbuster" drugs in its pipeline for near term commercialization.

Short term pain, long term gain!!

Wisee